OWP
JBIO

Old Well Partners’s Jade Biosciences JBIO Stock Holding History

Old Well Partners’s Portfolio JBIO Stock Details JBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-231
Closed -$237K – 34
2022
Q4 		$237K Buy
+231
New +$168K 0.21% 29
2022
Q1 		– Sell
-360
Closed -$149K – 35
2021
Q4 		$149K Hold
360
– – 0.09% 32
2021
Q3 		$264K Buy
+360
New +$202K 0.14% 25

Other funds holding JBIO

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Old Well Partners's JBIO Position: Q1 2023 in Review

Old Well Partners sold out of Jade Biosciences (JBIO) in Q1 2023, closing a stake of 231 shares — an estimated $237K sold.

Old Well Partners first reported a position in JBIO in Q3 2021 and held it in 3 quarters. The position peaked at $264K in Q3 2021. 64 funds tracked by Wall St. Rank hold JBIO as of Q1 2023.

  • Old Well Partners reported no remaining Jade Biosciences position as of Q1 2023 after selling out during the quarter.
  • Old Well Partners sold 231 Jade Biosciences shares in Q1 2023, an estimated $237K.
  • Old Well Partners first reported a position in Jade Biosciences in Q3 2021 and held it in 3 quarters.
  • Old Well Partners's Jade Biosciences position peaked at $264K in Q3 2021.
  • 64 funds tracked by Wall St. Rank held Jade Biosciences as of Q1 2023.

Based on Old Well Partners's 13F filing for Q1 2023, filed 15 May 2023.